LCM
NEUP

Lynx1 Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Lynx1 Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Hold
875,328
– – 0.44% 9
2026
Q1 		$3.56M Buy
875,328
+100
+0% +$423 0.56% 12
2025
Q4 		$3.4M Buy
+875,228
New +$6.22M 0.69% 12
2025
Q3 		– Sell
-45,806
Closed -$325K – 17
2025
Q2 		$325K Hold
45,806
– – 0.09% 13
2025
Q1 		$264K Hold
45,806
– – 0.09% 13
2024
Q4 		$157K Hold
45,806
– – 0.06% 17
2024
Q3 		$241K Sell
45,806
-4,167
-8% -$33K 0.09% 14
2024
Q2 		$460K Sell
49,973
-17,899
-26% -$195K 0.17% 12
2024
Q1 		$839K Sell
67,872
-820
-1% -$10.8K 0.22% 15
2023
Q4 		$1.22M Buy
68,692
+733
+1% +$20.9K 0.48% 13
2023
Q3 		$2.2M Buy
+67,959
New +$1.46M 1.46% 12

Other funds holding NEUP

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Lynx1 Capital Management's NEUP Position: Q2 2026 in Review

Lynx1 Capital Management held its Neuphoria Therapeutics (NEUP) position steady in Q2 2026 at 875,328 shares worth $3.83M. The position accounts for 0.44% of the portfolio, ranked #9.

Lynx1 Capital Management first reported a position in NEUP in Q3 2023 and has held it in 11 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Lynx1 Capital Management held 875,328 shares of Neuphoria Therapeutics worth $3.83M as of Q2 2026.
  • Lynx1 Capital Management left its Neuphoria Therapeutics share count unchanged in Q2 2026.
  • Neuphoria Therapeutics made up 0.44% of Lynx1 Capital Management's portfolio in Q2 2026, its #9 holding.
  • Lynx1 Capital Management first reported a position in Neuphoria Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.